BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius

Reuters

Apr 29, 2025

April 29 (Reuters) - SANDOZ GROUP AG SDZ.S:

SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS
SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS
AGREEMENT VALUED AT UP TO USD 301 MILLION
CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU
TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB
AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION

Source text: ID:nGNE8k7F37

Further company coverage: SDZ.S

(Gdansk Newsroom)

((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531754916"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531754916\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531754916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531754916","market":"nz","top_or_hot":-1,"title":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>SANDOZ GROUP AG <span>SDZ.S</span>:</p><ul><li><p>SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS</p></li><li><p>SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS</p></li><li><p>AGREEMENT VALUED AT UP TO USD 301 MILLION</p></li><li><p>CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU</p></li><li><p>TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB</p></li><li><p>AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION</p></li></ul><p>Source text: <span>ID:nGNE8k7F37</span></p><p>Further company coverage: <span>SDZ.S</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-29 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>SANDOZ GROUP AG <span>SDZ.S</span>:</p><ul><li><p>SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS</p></li><li><p>SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS</p></li><li><p>AGREEMENT VALUED AT UP TO USD 301 MILLION</p></li><li><p>CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU</p></li><li><p>TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB</p></li><li><p>AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION</p></li></ul><p>Source text: <span>ID:nGNE8k7F37</span></p><p>Further company coverage: <span>SDZ.S</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA3DHRXJ:1","article_id":"2531754916","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531754916","pubTimestamp":1745938928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With HenliusApril 29 (Reuters) - SANDOZ GROUP AG SDZ.S:SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADIN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖"},"translate_title":"简介-山德士集团与复宏汉霖签署全球合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9},"content_text":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With HenliusApril 29 (Reuters) - SANDOZ GROUP AG SDZ.S:SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONSSIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUSAGREEMENT VALUED AT UP TO USD 301 MILLIONCORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EUTO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMABAGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLIONSource text: ID:nGNE8k7F37Further company coverage: SDZ.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}